2 million Euro for Lophius Biosciences
The company founded from the University of Regensburg specialises in the development and marketing of innovative research reagents and diagnostic test kits for the functional analysis of disease associated T-cells. The current finance round of over 2 million € is being led by the already involved lead investor VRD GmbH, Heidelberg and complemented via investment by S-Refit AG, Regensburg and a further old investor. With the current investment development of various clinical indications of T-cell diagnostics and immunmonitoring should be advanced and the further development of the pipeline for the efficient diagnosis of tuberculosis and multiple sclerosis be supported. With the sealing of the finance round, Dr. Robert Phelps, to date director of business operations, was announed as the new managing director. The current managing director, Prof. Dr. Ralf Wagner, is changing with the end of his leave from the University of Regensburg as planned to the Supervisory Board at Lophius Biosciences and taking on chairmanship there.
For further information see: